• Chan, I.S.F., Bohidar, N.R., 1998. Exact power and sample size for vaccine efficacy studies. Commu. Stat-Theory Methods 27, 1305-1322.

  • Chen, D., Liu, C., Lv, H., Shi, H., Shang, J., Yin, Y., Luo, P., Luo, W., 2019. Investigation on rotavirus diarrhea in infants aged two years and below in Yuhan. Prev. Med. 31, 628-630 (In Chinese).

  • Chen, H., Li, Q., Duan, K., Shi, C., Zhang, D., Dong, B., Bai, X., Qiao, J., Xu, G., Yang, X., Gao, Z., Li, F., Lv, H., Zhou, H., Yan, T., Shi, H., 2021. Molecular epidemiological characteristics of rotavirus VP7 gene in zhengding county of Hebei province, xiangtan county of hunan province and yuhuan city of Zhejiang province, China from 2016 to 2017. Chin J Biologicals 34, 415-427 (In Chinese).

  • Ciarlet, M., Schodel, F., 2009. Development of a rotavirus vaccine:clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine. RotaTeq. Vaccine 27 (Suppl. 6), G72-G81.

  • Clements-Mann, M.L., Dudas, R., Hoshino, Y., Nehring, P., Sperber, E., Wagner, M., Stephens, I., Karron, R., Deforest, A., Kapikian, A.Z., 2001. Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants. Vaccine 19, 4676-4684.

  • De Vos, B., Han, H.H., Bouckenooghe, A., Debrus, S., Gillard, P., Ward, R., Cheuvart, B., 2009. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes:integrated analysis of randomized controlled trials. Pediatr. Infect. Dis. J. 28, 261-266.

  • Dhingra, M.S., Kundu, R., Gupta, M., Kanungo, S., Ganguly, N., Singh, M.P., Bhattacharya, M.K., Ghosh, R., Kumar, R., Sur, D., Chadha, S.M., Saluja, T., 2014.Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4)Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine 32 (Suppl. 1), A117-A123.

  • Fang, Z.Y., Wang, B., Kilgore, P.E., Bresee, J.S., Zhang, L.J., 2005. Sentinel hospital surveillance for rotavirus diarrhea in the People's Republic of China, August 2001-July 2003. J Infect Dis 192 (S), S94-S99.

  • Kulkarni, P.S., Desai, S., Tewari, T., Kawade, A., Goyal, N., Garg, B.S., Kumar, D., Kanungo, S., Kamat, V., Kang, G., Bavdekar, A., Babji, S., Juvekar, S., Manna, B., Dutta, S., Angurana, R., Dewan, D., Dharmadhikari, A., Zade, J.K., Dhere, R.M., Fix, A., Power, M., Uprety, V., Parulekar, V., Cho, I., Chandola, T.R., Kedia, V.K., Raut, A., Flores, J., 2017. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine 35, 6228-6237.

  • Lau, Y.L., Nelson, E.A., Poon, K.H., Chan, P.K., Chiu, S., Sung, R., Leung, C.W., Ng, D., Ma, Y.M., Chan, D., Lee, T.L., Tang, J., Kwan, Y.W., Ip, P., Ho, M., Fung, L.W., Tang, H., Suryakiran, P.V., Han, H.H., Bock, H., Hong Kong Rotarix Study, G., 2013.Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age:a randomized, controlled trial. Vaccine 31, 2253-2259.

  • Li, R.C., Huang, T., Li, Y., Luo, D., Tao, J., Fu, B., Si, G., Nong, Y., Mo, Z., Liao, X., Luan, I., Tang, H., Rathi, N., Karkada, N., Han, H.H., 2014. Human rotavirus vaccine(RIX4414) efficacy in the first two years of life:a randomized, placebo-controlled trial in China. Hum. Vaccines Immunother. 10, 11-18.

  • Liu, N., Xu, Z., Li, D., Zhang, Q., Wang, H., Duan, Z.J., 2014. Update on the disease burden and circulating strains of rotavirus in China:a systematic review and meta-analysis.Vaccine 32, 4369-4375.

  • Liu, Y., Li, Q., Bai, X., Jiang, Z., Zhang, J., Feng, D., Yang, B., Dong, B., Chen, T., Yan, T., He, S., Yang, Kejia, Li, F., Mo, Z., Wang, X., Xu, G., 2020. Epidemiological investigation on rotavirus diarrhea in infants at ages of less than 2 years in xiangtan county, hunan province and Rongshui county, Guangxi zhaung autonomous region, China. Chin. J. Biologicals. 33, 684-688 (In Chinese).

  • Mo, Z., Mo, Y., Li, M., Tao, J., Yang, X., Kong, J., Wei, D., Fu, B., Liao, X., Chu, J., Qiu, Y., Hille, D.A., Nelson, M., Kaplan, S.S., 2017. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants:a randomized, double-blind, placebo-controlled trial. Vaccine 35, 5897-5904.

  • National Medical Products Administration (NMPA), 2005. Guidelines for grading criteria of adverse events in clinical trials of preventive vaccines. (Registration No. 493).https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20051014010101369.html.

  • National Medical Products Administration (NMPA), 2019. Guidelines for grading criteria of adverse events in clinical trials of preventive vaccines. (Registration No.102). http s://www.nmpa.gov.cn/yaopin/ypggtg/ypqtgg/20191231111901460.html.

  • Phua, K.B., Lim, F.S., Lau, Y.L., Nelson, E.A., Huang, L.M., Quak, S.H., Lee, B.W., Van Doorn, L.J., Teoh, Y.L., Tang, H., Suryakiran, P.V., Smolenov, I.V., Bock, H.L., Han, H.H., 2012. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life:a randomized clinical trial in an Asian population. Vaccine 30, 4552-4557.

  • Vesikari, T., Karvonen, A.V., Majuri, J., Zeng, S.Q., Pang, X.L., Kohberger, R., Forrest, B.D., Hoshino, Y., Chanock, R.M., Kapikian, A.Z., 2006. Safety, efficacy, and immunogenicity of 2 doses of bovine-human (UK) and rhesus-rhesus-human rotavirus reassortant tetravalent vaccines in Finnish children. J. Infect. Dis. 194, 370-376.

  • Wang, S.J., Chen, L.N., Wang, S.M., Zhou, H.L., Qiu, C., Jiang, B., Qiu, T.Y., Chen, S.L., von Seidlein, L., Wang, X.Y., 2022. Genetic characterization of two G8P[8] rotavirus strains isolated in Guangzhou, China, in 2020/21:evidence of genome reassortment.BMC Infect. Dis. 22, 579.

  • Wang, L.P., Zhou, S.X., Wang, X., Lu, Q.B., Shi, L.S., Ren, X., Zhang, H.Y., Wang, Y.F., Lin, S.H., Zhang, C.H., Geng, M.J., Zhang, X.A., Li, J., Zhao, S.W., Yi, Z.G., Chen, X., Yang, Z.S., Meng, L., Wang, X.H., Liu, Y.L., Cui, A.L., Lai, S.J., Liu, M.Y., Zhu, Y.L., Xu, W.B., Chen, Y., Wu, J.G., Yuan, Z.H., Li, M.F., Huang, L.Y., Li, Z.J., Liu, W., Fang, L.Q., Jing, H.Q., Hay, S.I., Gao, G.F., Yang, W.Z., Chinese Centers for Disease Control and Prevention (CDC) Etiology of Diarrhea Surveillance Study Team, 2021.Etiological, epidemiological, and clinical features of acute diarrhea in China. Nat.Commun. 12, 2464.

  • Wang, X.Y., Riewpaiboon, A., von Seidlein, L., Chen, X.B., Kilgore, P.E., Ma, J.C., Qi, S.X., Zhang, Z.Y., Hao, Z.Y., Chen, J.C., Xu, Z.Y., 2009. Potential cost effectiveness of a rotavirus immunization program in rural China. Clin. Infect. Dis. 49, 1202-1210.

  • World Health Organization (WHO), 2007. Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccines (oral), Annex 3, TRS No 941. https://www.who.int/publications/m/item/oral-live-attenuated-rotavirus-vaccines-anne x-3-trs-no-941.

  • Wu, Z.W., Li, Q.L., Zhou, H.S., Duan, K., Gao, Z., Zhang, X.J., Jiang, Z.J., Hao, Z.Y., Jin, F., Bai, X., Li, Q., Xu, G.L., Zhao, Y.L., Yang, X.M., 2021. Safety and immunogenicity of a novel oral hexavalent rotavirus vaccine:a phase I clinical trial. Hum. Vaccines Immunother. 17, 2311-2318.

  • Zhang, J., Zhang, Y., Gao, Z., Liu, Y., Li, Q., Wu, Z., Su, T., Yang, Z., Zhao, Y., 2020. Monitoring results of rotavirus diarrhea in infants aged 0-24 months in a county of Hebei Province. Pract. Prev. Med. 27, 708-711.

  • Zhang, T., Li, J., Jiang, Y.Z., Xu, J.Q., Guan, X.H., Wang, L.Q., Chen, J., Liang, Y., 2022. Genotype distribution and evolutionary analysis of rotavirus associated with acute diarrhea outpatients in Hubei, China, 2013-2016. Virol. Sin. 37, 503-512.